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Abstract
Background: Despite enormous progress in gene therapy for breast cancer, an optimal systemic
vehicle for delivering gene products to the target tissue is still lacking. The purpose of this study
was to determine whether AC133+ progenitor cells (APC) can be used as both gene delivery
vehicles and cellular probes for magnetic resonance imaging (MRI). In this study, we used
superparamagentic iron oxide (SPIO)-labeled APCs to carry the human sodium iodide symporter
(hNIS) gene to the sites of implanted breast cancer in mouse model. In vivo real time tracking of
these cells was performed by MRI and expression of hNIS was determined by Tc-99m
pertechnetate (Tc-99m) scan.
Results: Three million human breast cancer (MDA-MB-231) cells were subcutaneously implanted
in the right flank of nude mice. APCs, isolated from fresh human cord blood, were genetically
transformed to carry the hNIS gene using adenoviral vectors and magnetically labeled with
ferumoxides-protamine sulfate (FePro) complexes. Magnetically labeled genetically transformed
cells were administered intravenously in tumor bearing mice when tumors reached 0.5 cm in the
largest dimension. MRI and single photon emission computed tomography (SPECT) images were
acquired 3 and 7 days after cell injection, with a 7 Tesla animal MRI system and a custom built
micro-SPECT using Tc-99m, respectively. Expression of hNIS in accumulated cells was determined
by staining with anti-hNIS antibody. APCs were efficiently labeled with ferumoxide-protamine
sulfate (FePro) complexes and transduced with hNIS gene. Our study showed not only the
accumulation of intravenously administered genetically transformed, magnetically labeled APCs in
the implanted breast cancer, but also the expression of hNIS gene at the tumor site. Tc-99m activity
ratio (tumor/non-tumor) was significantly different between animals that received non-transduced
and transduced cells (P < 0.001).
Conclusion: This study indicates that genetically transformed, magnetically labeled APCs can be
used both as delivery vehicles and cellular probes for detecting in vivo migration and homing of cells.
Furthermore, they can potentially be used as a gene carrier system for the treatment of tumor or
other diseases.
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Background
Breast cancer is the leading cause of death among women
[1,2]. Against substantial research over the past decades,
no definitive method for early detection and treatment of
the breast cancer has been found. Gene therapy holds
enormous therapeutic potential for breast cancer treat-
ment [3-12]. In cancer gene therapy, viral vectors are
administered locally or systematically [13]. Gene therapy
using replication competent viral vectors could deliver
their effects in two ways: 1) viral vectors can kill the tumor
cells by infecting them and replicating inside cells (onco-
lysis); or 2) viral vectors can be used to insert therapeutic
or suicidal genes, which can be targeted later [11,14].
When administered locally, however, the infiltrative
nature of the breast cancer poses a problem for the suc-
cessful delivery of genes to the sites of invading tumor
cells. In addition, several factors, including lack of an effi-
cient vector and delivery system, limit the effectiveness of
systemically delivered genes. Very recently, progenitor
cells have been used as carriers for therapeutic genes and
are considered as delivery vehicles for transferring exoge-
nous genes to the cancer cells [15,16]. In both cases, it is
necessary to monitor the migration and homing of the
genetically modified cells. However, current in vivo imag-
ing techniques lack the ability to track the real time migra-
tion and homing of genetically altered cells to cancer
tissue with acceptable resolution.
Labeling of cells with ferumoxides or other superparamag-
netic iron oxides (SPIO) to track the migration of labeled
cells is becoming routine in cellular MRI [17-22].
Recently, we have been able to magnetically label differ-
ent mammalian cells including hematopoietic stem cells
using two Food and Drug Administration (FDA)
approved agents: ferumoxide and protamine sulfate. Fer-
umoxide is an incomplete dextran coated SPIO agent with
an extremely high T2-relaxivity. It is used as contrast agent
for liver diseases [23,24]. We have shown a linear correla-
tion between relaxivity and iron concentration in labeled
cells [25]. Protamine sulfate is used clinically as antidode
for heparin toxicity. It has been shown that viability, func-
tionality, and differentiation capacity of labeled cells
(including stem cells) do not change after labeling
[19,26].
AC133+ cells are a subpopulation of CD34+ hematopoi-
etic stem cells, which are believed to be more pluripotent,
and incorporate into endothelial lining of neovessels in
normal and pathological conditions [27]. The purpose of
this study was to determine whether AC133+ progenitor
cells (APCs) can be used as gene delivery/carrier vehicles
and as cellular probes for MRI. We used superparamagen-
tic iron oxide (SPIO)-labeled AC133+ progenitor cells
(APCs) to carry the hNIS gene to sites of implanted breast
cancer in a mouse model. In vivo real time tracking of cells
was performed by MRI and expression of hNIS was deter-
mined by Tc-99m pertechnetate (Tc-99m) scan.
Results
Our experiments and data from other published papers
indicate that MDA-MB-231 is a slow growing breast can-
cer cell line. Tumor Xenografts will appear in nude mice 6
to 7 days after inoculation and grow to 0.5 to 0.7 cm in 14
days [28]. Our data showed that the tumor can have inter-
nal bleeding or surface ulceration when it grows to more
than 1.2 cm in a short period of time. Our main focus was
to track the administered APCs at the sites of active angio-
genesis in xenoplanted breast cancer, which is not related
to the presence or absence of estrogen receptor.
Efficiency of Iron Labeling
Labeling efficiency with FePro complexes was more than
90%, as determined by manual counting of PB-stained
and unstained cells using a microscope.
Mean Iron Concentration
Mean intra-cellular iron concentration was measured
based on a spectrophotometric method as described in
the Method Section. The iron concentration was deter-
mined from three different batches of labeled cells, which
were selected randomly during our experiments. The iron
concentration was 8.4 ± 2.8 pg per cell.
Viability of Labeled Cells
Magnetically labeled genetically transduced APCs showed
more than 75% viability compared to unlabeled non-
transduced cells, whereas control unlabeled or labeled
APCs were more than 90% viable.
Efficiency of Viral Transduction
Flowcytometric analysis indicated around 35% transduc-
tion efficiency using adenoviral vectors containing EGFP
gene (Figure 1). Follow up fluorescent microscopic exam-
ination indicated substantial number of EGFP positive
cells even after 12 days (Figure 1).
MRI Results
MR images clearly showed the presence of low signal
intensity areas around and inside the tumors in mice that
received iron labeled cells compared with the tumors that
received PBS only or unlabeled AC133+ cells, indicating
the accumulation of administered cells (Figures 2 and 3).
The presence of iron labeled cells was also confirmed by
PB staining (Figures 2 and 3).
Immunohistochemistry confirmed the accumulation of
NIS positive cells at the corresponding sites, as detected by
FITC labeled secondary antibodies (Figure 2G). These
findings prove that APCs can carry reporter or therapeutic
genes to the site of interest. In this case, they were foundBMC Biotechnology 2009, 9:28 http://www.biomedcentral.com/1472-6750/9/28
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at the periphery of the tumors where active angiogenesis
was observed. The accumulated cells also showed the
expression of endothelial markers such as CD31 (Figure
2H).
SPECT Analysis
SPECT image analysis showed that the ratio of the total
radioactivity (tumor/contralateral tissues) was signifi-
cantly higher in animals that received transduced cells
(Figures 2B, 2D) than those that received non-transduced
cells (Figure 3A). A comparison of the ratio of radioactiv-
ity among the different groups of animals is shown in Fig-
ure 4. Significantly increased radioactivity ratios were
observed in tumors of the animals that received magneti-
cally labeled transgenic AC133+ cells compared to that of
other groups both on days 3 and 7 (p < 0.05). There was
no significant difference in radioactivity observed
between days 3 and 7 in animals that received transgenic
cells (p-value > 0.05). There were also no significant dif-
ferences in the accumulated radioactivity in tumors
observed among animals that received either labeled or
unlabeled non-transgenic AC133+ cells. These findings
indicate that the increased accumulation of radioactivity
in tumors of animals that received transgenic cells is
related to the expression of hNIS in the migrated and
incorporated AC133+ cells. The hNIS bearing cells were
also confirmed by immunohistochemistry.
Figure 4 reflects our observation of non-specific increased
activity of Tc-99m at the site of tumors compared to the
contralateral muscle in animals that received either only
PBS or non-transduced unlabeled or labeled cells. This
non-specific activity might be due to increased blood vol-
ume in the tumors and extravasations of Tc-99m. How-
ever, this non-specific activity was significantly lower than
that found in tumors in animals that received transduced
cells.
Discussion
Experimental results confirmed our hypotheses that mag-
netically labeled transgenic APCs can be used as cellular
probes for MRI and gene carrier systems for breast cancer.
Gene delivery vehicle is a key tool in cancer gene therapy.
Carrier vehicles are needed for the delivery of therapeutic
genes to the target cancer cells. These vehicles should be
specifically targeted to the cancer cells. Lack of an appro-
priate carrier in addition to the infiltrative nature of breast
cancer is one of the main limitations of successful breast
cancer gene therapy [29]. To control the release of admin-
istered viruses into circulation, genetically transformed
cells are being considered for gene therapy for different
Transfection efficiency using adenoviral vectors containing  EGFP as a reporter gene Figure 1
Transfection efficiency using adenoviral vectors con-
taining EGFP as a reporter gene. Flowcytometric analy-
sis shows 30% to 35% EGFP positive cells in both cell 
populations. Fluorescent microscopy also shows EGFP posi-
tive cells in culture even after 12 days of infection.
Accumulation of magnetically labeled, transgenic AC133+  progenitor cells (APCs) around the implanted tumor Figure 2
Accumulation of magnetically labeled, transgenic 
AC133+ progenitor cells (APCs) around the 
implanted tumor. MRI shows low signal intensity areas at 
the margin of the tumor (A, C), which are at the correspond-
ing sites of iron positive cells detected by Prussian blue stain-
ing (E, F). The central low signal intensity areas are due to 
hemorrhagic foci within the tumor. B (trans-axial sections) 
and D (coronal sections) of SPECT studies indicate the accu-
mulated transgenic APCs that are detected by T-99m (within 
the white dotted oval ROI). The SPECT study also proves 
the migration and homing of APCs at the margin of the 
tumors (seen on MRI). Immunohistochemistry shows the 
accumulation of NIS positive cells and CD31 positive cells at 
the corresponding sites, as detected by labeled secondary 
antibodies (G, H). The findings prove that APCs can carry 
reporter or therapeutic genes to the site of interest (here at 
the site of active angiogenesis) and magnetically labeled APCs 
will act as probe for cellular MRI. MRI and SPECT of control 
unlabeled non-transduced AC133+ progenitor cells (I, J)
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tumors [30-35]. Due to its unique property to migrate to
the pathological lesions, stem cells are unique vehicles for
delivering therapeutic genes to the tumors, especially for
glioma [36-39]. Rat neural stem cells expressing the cyto-
sine deaminase gene, injected at a site distant from the pri-
mary tumor exhibit extensive migration and stable
expression of the gene, indicating persistent ability to
destroy tumor cells locally as well as distal from the main
tumor mass or metastatic foci [40]. Mesenchymal stem
cells, pluripotent bone marrow stromal cells, are also used
to carry genes to glioma and are considered effective deliv-
ery vehicles [39,41-43]. APCs, which are a subpopulation
of pluripotent hematopoietic stem cells showed active
migration and incorporation into the neovasculatures of
tumor when administered locally or systemically
[17,27,44]. Ferrari et al. [45] have shown the migration
and incorporation of HSV-tk transduced mouse APCs in
subcutaneous tumor in a mouse model, however, they did
not show incorporation of the transduced cells by in vivo
imaging. Our results support the findings of previous
reports that transgenic stem cells can migrate and accumu-
late at the sites of implanted tumors [46,47]. However, the
most important aspect of our study was that the transgenic
cells were tracked by in vivo imaging (both by MRI and
SPECT). To the best of our knowledge, this is the first
study to use different imaging modalities to show the
migration and accumulation of administered transgenic
stem cells. The findings of this proof-of-principle study
pave the road for further studies in other tumor models.
In recent years, imaging techniques that enable efficient
and non-invasive in vivo monitoring and tracking of trans-
planted cells have become central to the development of
cell transplantation based therapeutic approaches. Recent
studies using various disease models demonstrated that
MRI can be used as a high resolution imaging technique
for in vivo cell tracking [17-20]. Furthermore, MRI has
been successfully used to track the migration and incorpo-
ration of intravenously injected, magnetically labeled
APCs into the blood vessels in rodent tumor model
[17,27]. MRI along with the adequate labeling reagent
allow for monitoring of the entire time course of APC
migration. They also can show possible accumulation of
labeled cells in different tissues. In vivo detection and
measuring of gene expression using reporter genes is
another imaging ability. Reporter gene methods provide a
unique opportunity to study biology in living subjects.
They also allow for monitoring of physiological events in
an intact environment. NIS is a membrane glycoprotein
that mediates active iodide uptake in thyroid gland and
some other tissues [48]. Human NIS (hNIS) gene expres-
sion has been shown with radioisotopes of iodine and Tc-
99m-pertechnetate [49]. The hNIS has advantages over
other reporter genes such as HSV1-tk and luciferase in that
the hNIS gene product is innate and nonimmunogenic. It
has limited endogenic tissue-specific expression and can
mediate the uptake of chemically simple and available
radiopharmaceuticals. We have shown that transduced
APCs containing hNIS can easily be tracked and detected
using Tc-99m and SPECT. This confirms that our cells are
Accumulation of magnetically labeled, non-transgenic APCs  around the implanted tumor 7 days after IV administration Figure 3
Accumulation of magnetically labeled, non-trans-
genic APCs around the implanted tumor 7 days after 
IV administration. (A) Coronal sections of SPECT data 
indicating non-significant activity of Tc-99m at the tumor site 
(within the white circular ROI). MRI shows low signal inten-
sity areas at the periphery of the tumor (B, C, arrows), which 
are at the corresponding sites of iron positive cells detected 
by Prussian blue staining (D, E).
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Quantitative analysis of the ratio of total radioactivity of  tumor and contra-lateral muscle Figure 4
Quantitative analysis of the ratio of total radioactiv-
ity of tumor and contra-lateral muscle. There was no 
significant difference between total radioactivity of mice 
tumors injected by AC133 labeled transduced cells in 3 or 7 
days (p-value > 0.05). There was a significant difference 
between total radioactivity of the tumor with injected ed 
labeled cells and non-transduced cells for both AC133+ only 
and AC133+ labeled cells (p-value < 0.05).
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transduced by adenoviral vectors and hNIS is expressed in
the APCs at the tumor sites. Tumor histology in addition
to MRI analysis confirmed the presence of magnetically
labeled and genetically transduced cells at the periphery
of tumor where active angiogenesis was observed.
Limitations of this study are as follows. Viability of cells
after viral transduction was one limitation, although our
results were comparable to other published reports that
used viral vectors for transduction of stem cells [50]. The
overall transduction efficiency (we showed that 35% of
our cells were transduced), even with higher ratio of viral
particles, was low in our case using adenoviral vectors
because of a limited presence of CAR receptors on hemat-
opoetic cells [51]. However, the transduction was rela-
tively stable for at least 12 days. The use of lentiviral or
retroviral vectors would likely have produced more trans-
duced APCs [52]. Future projects will utilize different
effective viral vectors for relative stable transduction. We
are currently optimizing the virus-to-cell ratio to get more
viable cells after transduction and to get higher transduc-
tion efficiency. The timing of cell injection is another var-
iable that should be optimized. Multiple injections at
different time points in the same animal should also be
considered to increase the delivery of genes to the tumor
site.
Future Potential
The stem cell gene delivery system has the potential to
open a new window to the clinical cancer gene therapy.
APCs can be collected from patient's own peripheral
blood and bone marrow to avoid the immune system
reaction. An important application of our gene delivery
system is the delivery of suicidal genes to the cancer cells.
In this approach, genes such as HSV-TK/acyclovir (ACV),
ganciclovir (GCV), or herpes simplex virus-1-thymidine
kinase (HSV-TK) convert a non-toxic pro-drug into a toxic
drug. The bystander effect, a main phenomenon in this
treatment modality, occurs when neighboring cancer
cells, not specifically targeted with the suicidal gene, are
also destroyed. The cell-to-cell transfer of phosphorylated
GCV via gap junctions between HSV-TK transduced cells
and neighboring non-infected cells is the primary mecha-
nism for the bystander effect [53-55]. The efficacy of this
protocol will be directly related to the gene/pro-drug com-
bination and the target (cancer cells).
Conclusion
MRI and SPECT images showed accumulation of admin-
istered APCs in the implanted breast cancer and expres-
sion of hNIS gene, respectively. Our study indicates that
APCs can carry therapeutic genes even after systemic
administration. Genetically transformed, magnetically
labeled APCs can be used both as delivery vehicles and
cellular probes for detecting in vivo migration and homing
of cells by MRI. This method can be used in the future
development of gene therapy approaches where geneti-
cally modified cells can be tracked in real time and in vivo
by MRI in different disease processes.
Methods
AC133+ progenitor cells (APCs)
Fresh whole blood was obtained from the cord blood
under IRB approved protocol with proper informed con-
sent. Blood was collected in heparinized tubes. The blood
was diluted 1:2 in phosphate buffered saline (PBS) plus 2
mM EDTA (Ethylenediaminetetraacetic Acid), layered
onto lymphocyte separation medium (Ficoll, density
1.077 g/ml, ICN Biomedicals, Aurora, OH) and centri-
fuged for 30 minutes at 1,900 RPM, and at a temperature
of 20°C (35 ml blood was very gently added onto 15 ml
lymphocyte separation medium in every 50 ml sterile
tube). Then, the white ring fraction (mononuclear cell
layer) was transferred to a new 50 ml tube using a sterile
Pasteur pipette. PBS was added twice and the tubes were
centrifuged for 15 minutes at 1500 RPM at room temper-
ature. After discarding the supernatant, the pellet was
resuspended in 4 ml ACK lysine buffer to get rid of (for
lysing) remaining erythrocytes. Mononuclear cells
(MNCs) were incubated in the ACK lysine buffer for no
more than 3 minutes on ice. After 3 minutes, 20 ml PBS
was added to the solution, the cells were washed twice
(centrifuge at 1200 RPM) with PBS. MNCs were subjected
to immunomagnetic separation using AC133 Cell Isola-
tion Kit (Miltenyi Biotech; Auburn, CA; http://
www.miltenyibiotec.com), according to manufacturer's
instruction [56,57]. Briefly, MNCs were incubated for 45
minutes on ice with an FcR-blocking reagent (human IgG)
and AC133 MicroBeads. These microbeads are conjugated
with monoclonal mouse anti-human antibodies against
AC133. After washing with PBS plus 2 mM EDTA, the
labeled cells were filtered through a 30-μm nylon mesh
and loaded onto a column that was installed in a mag-
netic field. Trapped cells were eluted after the column was
removed from the magnet. The collected cells were named
AC133+ progenitor cells (APCs). APCs were grown in
stemline II media (Sigma, St. Louise, MO) supplemented
with 10 ng/ml of thrombopoietin (TPO), 40 ng/ml of
FLT3 and 40 ng/ml of stem cell factor (SCF). Initially, the
cells were suspended in media at 1 × 106 per ml and grown
in 5% CO2/95% air at 37°C in a humidified incubator
with fresh media added on every third day. The cells were
propagated for 7–10 days. On the day of labeling, the cells
were harvested and resuspended at a concentration of 4 ×
106 cells per ml. Collected cells were analyzed at different
days in culture for their phenotypical expression. There
were gradual declines in the expression of CD133 and
CD34, but the majority of cells were positive for CD31,
CXCR4 and CD117. Markers of lymphocytic (CD3,
CD19) and monocytic (CD14) lineages were absent.BMC Biotechnology 2009, 9:28 http://www.biomedcentral.com/1472-6750/9/28
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Breast Cancer Cells (MDA-MB-231)
Breast cancer cells (MDA-MB-231, ATCC, VA) were cul-
tured in 75-cm2 tissue culture flasks with Dulbecco's mod-
ified Eagle's medium (DMEM) supplemented with 10%
fetal bovine serum, penicillin (100 IU/mL), and strepto-
mycin (100 μg/mL) until they were 80–90% confluent.
Tumor Implantation
All animal studies were approved by the institutional ani-
mal care and user committee at Henry Ford Health Sys-
tem. Female nude mice (total 48 mice) were used for
implantation of tumor cells. Tumor cells (human breast
cancer), cultured in-vitro were harvested by trypsinization
and centrifugation, washed twice with PBS buffer, and
then resuspended in cell culture serum free media at a
concentration of 6 × 107 cells/ml. The animals received
one subcutaneous injection of 50 μl of cell suspension (3
million cells) in the right hind flank. These tumor cells are
efficient in making xenografted tumors with almost 90%
efficiency and show marked vascularity with less central
necrosis. Tumors were measured twice a week after
implantation in two dimensions. All animals received
intravenous injection of APCs when the tumor measured
between 0.5 to 1 cm diameter in the largest dimension.
Transduction of APCs with Adenoviral Vector Containing 
HSV-tk and hNIS Genes
An adenoviral vector carrying either the hNIS or EGFP
gene was used to transduce cells (Figure 5). Both vectors
also contained the HSV-tk gene, which can be used as a
suicidal gene for therapeutic purposes. hNIS and EGFP
acted as reporter genes and their activities were deter-
mined by Tc-99m pertechnetate (Tc-99m) SPECT and
flowcytometer, respectively. Cell to viral particle ratio was
maintained at 1:1000. Cells were at a concentration of 10
million per ml for initial 1 hour and then diluted ×10 with
complete culture media. Transduction efficiency was
determined on day 3 by flowcytometric analysis (using
EGFP as reporter gene) and fluorescent microscope. These
transgenic cells were magnetically (FePro) labeled on day
4 after transduction.
Labeling of Cells with Ferumoxide-Protamine Sulfate 
(FePro) Complex
The commercially available, FDA-approved SPIO, feru-
moxide suspension, (Feridex IV ®, Berlex Laboratories, Inc,
Wayne, New Jersey) contains particles approximately 80–
150 nm in size and has a total iron content of 11.2 mg/ml.
Protamine sulfate (American Pharmaceuticals Partner Inc.
Schaumburg, IL), supplied at 10 mg/ml, was prepared as
a fresh stock solution of 1 mg/ml in distilled water at the
time of use. Ferumoxide, at a concentration of 100 μg/ml,
was put into a mixing flask or tube containing serum-free
RPMI 1640 medium (Biosource, Camarillo, CA) contain-
ing non-essential amino acid, sodium pyruvate, and L-
glutamine. Protamine sulfate was then added to the solu-
tion at a concentration of 3–4.5 μg/ml of mixing media.
The solution containing ferumoxide and protamine sul-
fate was mixed for 30 seconds with intermittent hand
shakings. After 30 seconds, the FePro complex was added
directly to the cells, incubated for 2–3 hours, and then an
equal volume of the complete medium was added to the
cells, for a final concentration of 50 μg ferumoxide/ml of
medium. The cell suspension was then incubated over-
night. After overnight incubation, the cells were washed
three times and then resuspended in PBS.
Measuring Intracellular Iron
Intracellular iron concentration was measured based on
our previously published method by UV/VIS spectropho-
tometry [58]. In brief, cell suspensions with known cell
density were demineralized in 1 ml of 5 Mol/L hydrochlo-
ric acid for 4 hours. Then, the color of the mixture was
read with a UV/VIS spectrometer at 351 nm wave-length.
The absorption value was normalized to a standard curve
generated from a known solution of ferumoxide. To deter-
mine the very low concentration of iron in the sample, the
iron concentration was measured using this method and
is expressed as an average picogram of iron/cell. Cur-
rently, this method is used in our laboratory to determine
the very low concentration of iron in the sample. The
commercially available kit for measuring iron concentra-
tion was not sensitive enough to detect such low iron con-
centrations (< 1 μg/ml).
Determination of Labeling Efficiency
After incubation with FePro, the cells were washed 3 times
in the presence of heparin sulfate to remove excess FePro
and transferred to cytospin slides. Cells were fixed and
Adenovirus design to detect transfected efficiency by flowcy- tometric (EGFP) and nuclear medicine (hNIS using Tc-99m)  techniques Figure 5
Adenovirus design to detect transfected efficiency by 
flowcytometric (EGFP) and nuclear medicine (hNIS 
using Tc-99m) techniques. This figure is printed with the 
permission of Kenneth N Barton from the Radiation Oncol-
ogy Department of Henry Ford Hospital.BMC Biotechnology 2009, 9:28 http://www.biomedcentral.com/1472-6750/9/28
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stained with Perl's reagent for Prussian blue (PB) staining.
FePro labeling efficiency was determined by manually
counting PB stained and unstained cells using a micro-
scope at 40× magnification. Cells were considered PB pos-
itive if intracytoplasmic blue granules were detected. The
percentage of labeled cells was determined from the aver-
age of 5–10 high-powered fields.
Cellular viability of FE-Pro labeled cells
After labeling, the cells were washed at least twice with
sterile PBS and then resuspended in PBS at a concentra-
tion of 3 × 107 cells/ml. A small aliquot of cells were
mixed with trypan blue dye and checked under a micro-
scope to determine cell viability.
Intravenous Administration of hNIS Transduced and FePro 
Labeled APCs
Either hNIS transduced and FePro labeled APCs or control
APCs (without transduction and labeling) were adminis-
tered intravenously into tail vein of mouse when the
tumor grew to 0.5 cm in size (along the largest dimen-
sion). A total of three million APCs in 200 μl was admin-
istered intravenously. Following administration of APCs,
mice underwent MRI and Tc-99m SPECT scanning to
determine the migration and accumulation of FePro
labeled and transgenic (containing hNIS) cells, respec-
tively, on days 3 and 7 after cell administration.
Magnetic Resonance Imaging Study
Preparation
Anesthesia was induced and maintained during all MRI
studies using an inhalation mixture of isoflurane (3% for
induction and 0.5–1.5% for maintenance) in a 2:1 N2O/
O2 gas mixture, with the animal breathing spontaneously.
After induction, the animal was placed in a custom made
MRI compatible Plexiglas holder that was equipped a
nose cone for the delivery of gasses and a heating pad.
After securing the animal's nose inside the mask, the hind-
quarters of the animal were positioned and secured to the
holder, a rectal probe was inserted for temperature moni-
toring, and the holder was placed inside the imaging coil.
Next, the animal holder/imaging coil assembly was
placed inside the magnet, isoflurane was reduced to 0.5–
1.5%, and the animal's core temperature maintained at
37°C using a feedback controlled water bath.
MRI Systems
MRI experiments were conducted using either a 7 Tesla (7
T) or a 3 Tesla (3 T) MRI system. The 7 T system is a 12 cm
(clear bore) magnet (Magnex Scientific, Inc., Abingdon,
UK) interfaced to a Bruker console (Bruker Biospin MRI,
Inc, Billerica, MA) with actively shielded gradients of 25
gauss/cm and 100 μs rise time. A 5 cm diameter quadra-
ture birdcage RF coil tuned to 300 MHz is used for RF
transmission and reception. The 3 T system is a whole
body magnet (Signa Excite, GE health, Milwaukee, WI)
that uses dedicated small animal coils (Doty scientific) for
animal imaging. Once inside the magnet, the position of
the animal was adjusted so that the central imaging slice
coincided with the center of the tumor.
T2 Measurement using 7 T System
Multi-slice T2-weighted images were acquired using a
multi-echo spin-echo sequence with a fixed repetition
time (TR) and progressively incremented echo times (TE)
[TR/TE = 3000/12, 24, 36, 48 ms]. Imaging parameters
were as follows: FOV = 32 mm, matrix = 256 × 256, 17
slices (interleaved slice acquisition), slice thickness = 1
mm. The total scan time was approximately 13 minutes.
Susceptibility Weighted Imaging (SWI) using 7 T System
This is a specialized 3D gradient-echo sequence, very sen-
sitive to the presence of iron and can detect iron labeled
cells. The method uses TR/TE = 50 ms/6.7 ms, flip angle =
15 degrees, BW = 50 KHz, 32 × 32 × 16 mm3 FOV, 256 ×
256 × 64 matrix (resolution of 125 × 125 × 250 mm3), 2
averages with flow compensation applied in all three
directions. The total scan time for this 3D data set was
approximately 27 minutes.
T2 Measurement using 3 T System
Multi-slice T2 images were acquired using a Carr, Purcell,
Meiboom, and Gill (CPMG) multi-echo spin-echo
sequence with a fixed repetition time (TR) and progres-
sively incremented echo times (TE) [TR/TE = 2400/15, 30,
45, 60 ms]. The imaging parameters were as follows: FOV
= 35 mm, matrix = 160 × 128, averages = 3, 15 slices, slice
thickness = 1 mm. The total scan time was approximately
5 minutes.
T2* Measurements using 3 T System
Multi-slice T2* images were acquired using a multi-echo
gradient-echo sequence with a fixed repetition time (TR)
and progressively incremented echo times (TE) [TR/TE =
600/10, 15, 20, 30 ms]. The imaging parameters were as
follows: FOV = 35 mm, matrix = 160 × 128, averages = 4,
15 slices, slice thickness = 1 mm. The total scan time was
approximately 8 minutes.
FIESTA using 3 T System
This is a specialized 3D gradient-echo sequence, very sen-
sitive to the presence of iron and can detect iron labeled
cells. The method uses TR/TE = 11–15 ms/3–7 ms, flip
angle = 40 degrees, BW = 10 kHz, 60 × 60 × 40 mm3 FOV,
300 × 300 × 200 matrix (resolution of 200 × 200 × 200
mm3), 2 averages. The total scan time for this 3D data set
was approximately 15 minutes.
SPECT Study
Within 24 hours after MRI, animals underwent SPECT
studies using Tc-99m to determine the status of geneti-
cally transformed cells at the sites of tumors. Animals wereBMC Biotechnology 2009, 9:28 http://www.biomedcentral.com/1472-6750/9/28
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anesthetized using ketamine/xylazine (100/15 mg/kg)
and received 1 mCi of Tc-99m through tail vein injection
in a volume of 200 μl. 60 minutes after Tc-99m injection,
animals were wrapped with padded sheet to keep them
warm and placed in the imaging holder under anesthesia.
SPECT images were acquired with a dedicated PRISM
3000 gamma camera fitted with mutli-pinhole mouse col-
limator, 360 degree rotation with 36 degree increments,
180 sec per projection, using 256 × 256 matrices with a
field of view of 4 × 6 cm. The total time required for
acquiring SPECT images was about 31 minutes.
Euthanasia and Histological Analysis
Immediately after SPECT imaging, the animals were anes-
thetized using pentobarbital (100 mg/kg intravenous or
intraperitoneal) and sacrificed. The tissues were fixed for
histological analysis by perfusion with saline, for vascular
washout, followed by paraformaldehyde. The radioactive
fluids were collected and contained in a shielded area to
decay. The animals were euthanized either with 100 mg/
kg of pentobarbital administration (intravenous or intra-
peritoneal). The whole tumor and part of surrounding tis-
sues (muscles and skin) were collected for histochemical
determination of iron labeled cells using PB staining and
markers of endothelial cells, such as CD31 and vWF using
human specific antibodies (BD Pharmingen and DakoCy-
tomation respectively). Expression of hNIS in accumu-
lated cells was determined by staining with anti-hNIS
antibody (Genetex, TX, USA).
Study Design
There were four groups of animals (n = 6/group) for each
time point (days 3 and 7 after IV administration of cells):
1) controls injected with PBS: 2) tumors injected with
unlabeled APCs; 3) tumors injected with magnetically
labeled APCs; and 4) tumors injected with transduced and
magnetically labeled APCs. The total number of animals
used in the study was 48.
Image and Statistical Analysis
Eigentool image analysis software (Henry Ford Hospital,
Detroit, MI, USA) was used to analyze MRI images. Eigen-
tool has a comprehensive set of functions for displaying,
restoring, enhancing, and analyzing images [59-61]. Sta-
tistical analysis of SPECT images was performed with SPSS
software (version 13; SPSS Institute Inc.) for Microsoft
Windows. The data were analyzed with two-way analysis
of variance and general linear models. The significance
level was set at 0.05 and statistical analysis of the tumor-
to-muscle ratio was performed with constructed SPECT
images. ImageJ software was also used for SPECT analysis.
Tumor volume was defined on the SPECT images by draw-
ing ROIs around the tumor on each slice and the total
activity was recorded. The same volume was used to com-
pute the total activity from the contra-lateral muscle
region.
The percentage of change in the total activity (ΔTa%) was
calculated using:
ΔTa% = 100 × (TaT-TaM)/TaM (1)
where TaT is the total activity of the tumor and TaM is the
total activity of the contralateral muscle for the same vol-
ume as that of the tumor.
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